WHO ICTRP trial
A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with…
NL-OMON49166 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON49166 |
|---|---|
| Public title | A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine - PIONEER-PEDS2 |
| Scientific title | A Phase 3, 12-Month, Open-Label Study of Lasmiditan in Pediatric Patients with Migraine - PIONEER-PEDS2 - H8H-MC-LAHW (PIONEER-PEDS2) |
| Primary sponsor | Eli Lilly |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Belgium;Canada;Czechia;France;Germany;India;Italy;Japan;Mexico;Netherlands;Romania;Russian Federation ;Spain;United Kingdom;United States of America |
| Conditions | Headache; migraine;10019231;Headache; migraine |
| Interventions | Participants will be randomized in a 1:1 ratio at study entry to treatment with weight-based doses corresponding to the medium dose- and the high dose adult exposure (referred to throughout as lasmiditan medium dose and lasmiditan high… |
| Registration date | May 24, 2022 |
| Target size | 3 |
| Secondary IDs | 2019-004379-38;NL73491.075.20 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: